Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury
Bright, J.McIntosh.; Dowers, K.; Powers, B.E.
Veterinary Therapeutics Research in Applied Veterinary Medicine 4(1): 35-46
2003
ISSN/ISBN: 1528-3593 PMID: 12756634 Document Number: 565210
An established model of arterial injury was used to evaluate the ability of the glycoprotein (GP) IIb/IIIa antagonist abciximab to inhibit platelet function and deter thrombus formation in cats. The study was a blinded evaluation, with control cats receiving aspirin and placebo and treatment cats receiving aspirin plus abciximab. The group treated with aspirin plus abciximab had significantly (P<.05) less thrombus formation based on a smaller number and frequency of cyclic flow reductions and reduced luminal thrombus area than cats treated with aspirin plus placebo. Abciximab administered in addition to aspirin also resulted in significant (P<.05) inhibition of platelet function based on mucosal bleeding time and change in bleeding time from baseline.